Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Mayne Pharma International Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (62)
Cancellation by sponsor (37)
Australian Public Assessment Report (AusPAR) (5)
Prescription medicine registration (5)
Prescription medicine decision summary (1)
Prescription medicine evaluation (1)

Date

2026 (3)
2025 (5)
2024 (3)
2023 (14)
2022 (11)
2021 (5)
2020 (9)
2019 (4)
2018 (13)
2017 (7)
2015 (2)
2014 (3)
2013 (3)
2012 (4)
2010 (1)
2009 (1)
2007 (1)
2004 (2)
2002 (1)
1999 (1)
1996 (6)
1994 (3)
1991 (9)

Search

Sponsor content

111 result(s) found, displaying 71 to 80

EPOPROSTENOL MYX epoprostenol (as sodium) 500 microgram powder for injection vial with diluent vial Cancelled under Section 30(1)(c) of the Act

30 April 2018

Cancellation by sponsor

Requested by Mayne Pharma International Pty Ltd
EPOPROSTENOL MYX epoprostenol (as sodium) 1.5 mg powder for injection vial with diluent vial Cancelled under Section 30(1)(c) of the Act

30 April 2018

Cancellation by sponsor

Requested by Mayne Pharma International Pty Ltd
Mayne Pharma International Pty Ltd - Epidermal osmotic dressing, non-sterile (227128)

20 August 2014

ARTG

Australian Register of Therapeutic Goods (ARTG) information for Mayne Pharma International Pty Ltd - Epidermal osmotic dressing, non-sterile.
AusPAR: Silodosin

14 November 2017

Australian Public Assessment Report (AusPAR)

Silodosin
LOZANOC itraconazole 50 mg capsule blister pack (206361)

16 April 2014

ARTG

Australian Register of Therapeutic Goods (ARTG) information for LOZANOC itraconazole 50 mg capsule blister pack.
LOZANOC itraconazole 50 mg capsule bottle (206360)

16 April 2014

ARTG

Australian Register of Therapeutic Goods (ARTG) information for LOZANOC itraconazole 50 mg capsule bottle.
AusPAR: Ephedrine Hydrochloride

12 July 2017

Australian Public Assessment Report (AusPAR)

Australian Public Assessment Report for Ephedrine Hydrochloride
Lozanoc 50 mg capsules (216603)

25 October 2013

ARTG

Australian Register of Therapeutic Goods (ARTG) information for Lozanoc 50 mg capsules.
TRANEXAMIC ACID MYX tranexamic acid 1000 mg/10 mL solution for injection ampoule Cancelled under s30(1)(c)

30 May 2017

Cancellation by sponsor

Requested by Mayne Pharma International Pty Ltd
TRANEXAMIC ACID MYX tranexamic acid 1000 mg/10 mL solution for injection ampoule Cancelled under s30(1)(c) of the Act

30 May 2017

Cancellation by sponsor

Requested by Mayne Pharma International Pty Ltd

Pages

First page
Previous page
…
Page 4
Page 5
Page 6
Page 7
Current page 8
Page 9
Page 10
Page 11
Page 12
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.